Galantamine: reports of serious skin reactions

Serious skin reactions have occurred in patients taking the Alzheimer's treatment galantamine (Reminyl), the manufacturer has highlighted in a letter to healthcare professionals.

Galantamine is licensed for the treatment of mild to moderately severe Alzheimer's dementia. | iSTOCK
Galantamine is licensed for the treatment of mild to moderately severe Alzheimer's dementia. | iSTOCK

Five cases of serious skin reactions, including Stevens-Johnson syndrome (SJS), acute generalised exanthematous pustulosis (AGEP) and erythema multiforme have been reported in patients taking galantamine.

Discontinue if rash occurs

Further information
View Reminyl drug records
Letter to healthcare professionals
Summaries of Product Characteristics

Patients being treated with galantamine should be advised to discontinue treatment and seek medical help immediately if any of the following symptoms occur:

  • severe rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (SJS).
  • red rash covered with small pus-filled bumps that can spread over the body, sometimes with a fever (AGEP).
  • rash that may blister, with spots that look like small targets (erythema multiforme).
All serious suspected adverse reactions associated with galantamine should be reported in accordance with the MHRA Yellow Card Scheme.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more